DPP4 and hepatocellular carcinoma: In the subgroup analysis (Figure 3), the use of DPP-4 inhibitors was shown to be beneficial in the prevention of HCC, and the incidence of HCC was generally lower among the subgroups within DPP-4 inhibitors users compared within non-DPP-4 inhibitors users.